Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/26/2011EP2378878A1 Inhibitors of diacylglycerol acyltransferase
10/26/2011EP2378877A1 Imidazolinone derivatives as cgrp receptor antagonists
10/26/2011EP2378876A1 Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
10/26/2011EP2378873A1 Method of treating neuropathic pain
10/26/2011EP2378872A1 Acne vulgaris treatment regimen
10/26/2011EP2252278B1 Beta-2 adrenergic agonists for use in the treatment of chronic neuropathic allodynia
10/26/2011EP2238110B1 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
10/26/2011EP2185546B1 Co-crystals and pharmaceutical compositions comprising the same
10/26/2011EP2181985B1 Antiviral Agent
10/26/2011EP2176250B1 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
10/26/2011EP2167069B1 Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
10/26/2011EP2150530B1 Substituted sulfonamide derivatives
10/26/2011EP2142538B1 Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
10/26/2011EP2142169B1 Aqueous pharmaceutical preparation
10/26/2011EP2139894B1 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
10/26/2011EP2136788B1 Cancer cell targeting using nanoparticles
10/26/2011EP2131849B1 Compositions and methods for delivery of anti-cancer agents
10/26/2011EP2129374B1 Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
10/26/2011EP2117562B1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
10/26/2011EP2117535B1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
10/26/2011EP2091320B1 SORPTION MEDIUM process of production und use
10/26/2011EP2066636B1 5-phenyl-nicotinamide derivatives
10/26/2011EP2061452B1 Anti cancer use of caffeic acid and derivatives
10/26/2011EP2057141B1 Pyrimidone compounds as gsk-3 inhibitors
10/26/2011EP2037739B1 Benzyl-substituted quinolone m1 receptor positive allosteric modulators
10/26/2011EP2026788B1 Therapeutic combination for painful medical conditions
10/26/2011EP2022786B1 Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep
10/26/2011EP2004176B1 USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY
10/26/2011EP2001848B1 Piperidines and related compounds for the treatment of dementia
10/26/2011EP1988772B1 Compounds for the treatment of metabolic disorders
10/26/2011EP1943219B1 5-lipoxygenase-activating protein (flap) inhibitors
10/26/2011EP1916245B1 Indole derivative having pgd2 receptor antagonist activity
10/26/2011EP1871395B1 Garlic extract and chitosan compositions, and uses thereof
10/26/2011EP1846394B1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
10/26/2011EP1756112B1 Pyrrolobenzimidazolones and their use as antiproliferative agents
10/26/2011EP1631293B1 Compounds, formulations, and methods for treating or preventing rosacea
10/26/2011EP1587477B1 Odorless formulation for treating mucosal discontinuities
10/26/2011EP1575509B1 Epha2 agonistic monoclonal antibodies and methods of use thereof
10/26/2011EP1518855B1 Diaminopyrimidinecarboxa mide derivative
10/26/2011EP1496056B1 Novel compounds and antimalarials
10/26/2011EP1438378B1 Cholesterol lowering structured lipids with omega 6 pufa
10/26/2011EP1429729B1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin
10/26/2011EP1427810B1 Method and quantification assay for determining c-kit/scf/pakt status
10/26/2011EP1425010B1 Substituted indoles and their use as integrin antagonists
10/26/2011EP1296642B1 Use of creatine and/or creatine derivatives in dermatological preparations
10/26/2011EP1259481B1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same
10/26/2011CN1980934B Novel indole derivatives as selective androgen receptor modulators (sarms)
10/26/2011CN1901922B Compositions and uses thereof
10/26/2011CN1827776B Method for predicting calcium antagonist medicine effect and application thereof
10/26/2011CN1762967B Enoxolone derivative, preparation method and uses
10/26/2011CN1662243B Pharmaceutical composition
10/26/2011CN1607204B Cyclophosphamide quaternary ammonium salt derivant and its synthesis and use
10/26/2011CN102227448A Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof
10/26/2011CN102227436A Macrocyclic compounds as hepatitis c virus inhibitors
10/26/2011CN102227435A Hepatitis c virus inhibitors
10/26/2011CN102227432A Process for preparing chlorins and their pharmaceutical uses
10/26/2011CN102227431A Indole and indoline derivatives and methods of use thereof
10/26/2011CN102227430A Modulators of cystic fibrosis transmembrane conductance regulator
10/26/2011CN102227429A 3-aminocyclopentanecarboxamides as chemokine receptor modulators
10/26/2011CN102227428A Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
10/26/2011CN102227427A Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug
10/26/2011CN102227426A Benzonaphtyridine compounds used as inhibitors of autotaxin
10/26/2011CN102227425A Azaindazole compounds as ccr1 receptor antagonists
10/26/2011CN102227424A Modulators of cystic fibrosis transmembrane conductance regulator
10/26/2011CN102227422A Heterocyclic jak kinase inhibitors
10/26/2011CN102227421A Anti-proliferation compounds
10/26/2011CN102227420A Quinazolinone, quinolone and related analogs as sirtuin modulators
10/26/2011CN102227419A Anhydrate and hydrate forms of strontium ranelate
10/26/2011CN102227417A Chromenone analogs as sirtuin modulators
10/26/2011CN102227416A Method for producing phenolphthalein using heteropolyacid catalyst
10/26/2011CN102227411A Antibacterial compounds
10/26/2011CN102227410A Bis [o-(14-benzoylaconine-8-yl)] esters
10/26/2011CN102227409A Pyridine-3-carboxyamide derivative
10/26/2011CN102227407A Hepatitis c virus inhibitors
10/26/2011CN102227237A Host cell kinases as targets for antiviral therapies against hcv infection
10/26/2011CN102227228A Use of carboxymethylcellulose to control ejectability and solidification of time of compositions one or more bioresorbable ceramics
10/26/2011CN102227223A Mineral absorption improver, and method for improving absorption of minerals
10/26/2011CN102227222A Antitumor agent, method for production of said agent and method for stabilisation thereof
10/26/2011CN102227221A Pharmaceutical combination containing hsp90 inhibitor and mtor inhibitor
10/26/2011CN102227220A Hsp90 inhibitors for therapeutic treatment
10/26/2011CN102227219A Substituted pyrazole compounds
10/26/2011CN102227218A Tnik inhibitor and use thereof
10/26/2011CN102227217A Methods and compositions for improving cognitive function
10/26/2011CN102227216A Pharmaceutical dosage form comprising nifedipine or nisoldipine and angiotensin-ii antagonist and/or diuretic
10/26/2011CN102227212A Novel ezetimibe formulations
10/26/2011CN102227211A Pharmaceutical formulation comprising diclofenac and hydroxy fatty acid polyoxyalkylene ester
10/26/2011CN102226791A Method for determining dehydroandrographolide content in Ganmaoqing capsule by high performance liquid chromatography
10/26/2011CN102225970A Extraction method of polysaccharide from potentilla discolor
10/26/2011CN102225962A New derivative bonded by berberine and cholic acid at 9th position of berberine and preparation method thereof
10/26/2011CN102225961A Novel berberine 9-position coupled cholic acid derivative and preparation method thereof
10/26/2011CN102225955A Method for safely and efficiently converting ganglioside GM1
10/26/2011CN102225940A Isosorbide benzoate compound as well as preparation method and medicinal use thereof
10/26/2011CN102225937A Antineoplastic alkaloid compound, and its medicine composition, preparation method and application
10/26/2011CN102225929A Compound of stable Fasudil hydrochloride hydrate
10/26/2011CN102225926A Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
10/26/2011CN102225921A Cyclopentane polyketide simplextone A and its application
10/26/2011CN102225919A Curcumin analogue and preparation method thereof as well as application of analogue in preparation of Alzheimer disease resisting medicament
10/26/2011CN102225914A 3-alkenyl-4-aldehyde-5-aryl-4-isoxazoline compound, preparation method thereof and purpose thereof
10/26/2011CN102225913A Rheinic acid derivatives and treatment application thereof
10/26/2011CN102225903A Amidino guanido substituted aromatic heterocyclic copmound and synthesis and use thereof
1 ... 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 ... 7860